Related Experiment Video
Updated: Aug 11, 2026
Application of Lucilia sericata Larvae in Debridement of Pressure Wounds in Outpatient Settings
Published on: December 4, 2021
Larval Therapy for Treatment of Chronic Wounds Colonized by Multi-resistant Pathogens in a Pediatric Patient: A Case
Gemma Pérez-Acevedo1,2,3, Alejandro Bosch-Alcaraz1,2,3, Joan Enric Torra-Bou1,2,3
1Gemma Pérez-Acevedo, RN, PNP, MSc, Sant Joan de Déu Hospital, Esplugues de Llobregat, Barcelona, Spain.
Background:
Chronic wounds are susceptible to colonization with gram-positive and gram-negative bacteria that may be resistant to antimicrobial dressings and systemic antibiotics. In January 2004, the US Food and Drugs Administration approved use of medicinal larvae for use in humans and animals for resistant organisms. Despite use in adults, there is a paucity of evidence evaluating its efficacy and safety in the pediatric population.
Case:
T was a 5-year-old boy with several chronic wounds infected with multidrug-resistant Pseudomonas aeruginosa. The wounds were originally treated with chemical debridement, dressings containing ionic silver, negative-pressure wound therapy (NPWT), and antibiotics without success. Consequently, a multidisciplinary team implemented maggot debridement therapy (MDT).
Conclusions:
After MDT, one wound completely epithelialized and the other wounds achieved a reduction in size with 70% epithelization. Therapy also led to a reduction in wound odor, exudate, and pain. The other wounds were closed after additional management with dressing containing nanocrystalline silver and NPWT.
Insights
Maggot debridement therapy (MDT) successfully treated chronic wounds in a pediatric patient infected with multidrug-resistant bacteria. This approach offers a promising alternative for complex wound management in children.
Area of Science:
- Medical entomology
- Wound care science
- Pediatric infectious diseases
Background:
- Chronic wounds frequently harbor multidrug-resistant bacteria, complicating treatment with conventional antimicrobial dressings and systemic antibiotics.
- The US Food and Drug Administration approved medicinal larvae (maggots) for treating resistant infections in humans and animals in 2004.
- Evidence for the efficacy and safety of maggot debridement therapy (MDT) in pediatric populations remains limited.
Observation:
- A 5-year-old boy presented with chronic wounds infected by multidrug-resistant Pseudomonas aeruginosa.
- Previous treatments including chemical debridement, silver dressings, negative-pressure wound therapy (NPWT), and antibiotics were unsuccessful.
- A multidisciplinary team initiated maggot debridement therapy (MDT) for the resistant wound infections.
Findings:
- Following MDT, one wound achieved complete epithelialization, while other wounds showed significant improvement with 70% epithelization and reduced size.
- MDT effectively decreased wound odor, exudate, and pain levels.
- Additional treatment with nanocrystalline silver dressings and NPWT facilitated the closure of the remaining wounds.
Implications:
- Maggot debridement therapy (MDT) demonstrates significant potential for managing chronic, multidrug-resistant infections in pediatric wound care.
- This case highlights MDT as a viable therapeutic option when standard treatments fail.
- Further research into MDT's pediatric application is warranted to establish its safety and efficacy profile.
